Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31,883 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis.
Chiorean MV, Allegretti JR, Sharma PP, Chastek B, Salese L, Bell EJ, Peterson-Brandt J, Cappelleri JC, Guo X, Khan N. Chiorean MV, et al. Among authors: guo x. BMC Gastroenterol. 2022 Jul 26;22(1):356. doi: 10.1186/s12876-022-02298-7. BMC Gastroenterol. 2022. PMID: 35883049 Free PMC article. No abstract available.
Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Sustain.
Allegretti JR, Gecse KB, Chiorean MV, Argollo M, Guo X, Lawendy N, Su C, Mundayat R, Paulissen J, Salese L, Irving PM. Allegretti JR, et al. Among authors: guo x. J Gastroenterol Hepatol. 2024 Feb;39(2):264-271. doi: 10.1111/jgh.16386. Epub 2023 Nov 12. J Gastroenterol Hepatol. 2024. PMID: 37953548
Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure.
Panés J, D'Haens GR, Sands BE, Ng SC, Lawendy N, Kulisek N, Guo X, Wu J, Vranic I, Panaccione R, Vermeire S. Panés J, et al. Among authors: guo x. United European Gastroenterol J. 2024 Jul;12(6):793-801. doi: 10.1002/ueg2.12584. Epub 2024 May 22. United European Gastroenterol J. 2024. PMID: 38778549 Free PMC article.
Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study.
Vavricka SR, Greuter T, Cohen BL, Reinisch W, Steinwurz F, Fellmann M, Guo X, Lawendy N, Paulissen J, Peyrin-Biroulet L. Vavricka SR, et al. Among authors: guo x. Therap Adv Gastroenterol. 2022 May 10;15:17562848221090834. doi: 10.1177/17562848221090834. eCollection 2022. Therap Adv Gastroenterol. 2022. PMID: 35574426 Free PMC article.
Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.
Sandborn WJ, D'Haens GR, Sands BE, Panaccione R, Ng SC, Lawendy N, Kulisek N, Modesto I, Guo X, Mundayat R, Su C, Vranic I, Panés J. Sandborn WJ, et al. Among authors: guo x. J Crohns Colitis. 2023 Apr 3;17(3):338-351. doi: 10.1093/ecco-jcc/jjac141. J Crohns Colitis. 2023. PMID: 36124702 Free PMC article. Clinical Trial.
31,883 results
You have reached the last available page of results. Please see the User Guide for more information.